Outcome of combined modality treatment including neoadjuvant chemotherapy of 128 cases of locally advanced breast cancer: Data from a tertiary cancer center in northern India

Indian Journal of Cancer

Volumn 48, Issue 1, 2011, Pages 80-85

  Raina, V ^a   Kunjahari, M ^a   Shukla, N K ^a   Deo, S V S ^a   Sharma, A ^a   Mohanti, B K ^a   Sharma, D N ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

combined modality treatment; Locally advanced breast cancer; neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; INDIA; LOCALLY ADVANCED BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDIA; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951996080     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.75838     Document Type: Article

References (30)

1. Two-year Report of the Population Based Cancer Registries: 1999-2000. National Cancer Registry Programme (Indian Council of Medical Research).
2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI. et al. Revision of American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628-36. (Pubitemid 34983222)
3. Valero V V, Buzdar AU, Hortobagyi GN . The Oncologist 1996;1:8-17.
4. Klefstrom P, Grohn P, Heinonen E, Holsti L, Holsti P. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. Cancer 1987;60:936-42.
5. Toonkel LM, Fix I, Jacobson LH, Bamberg N, Wallach CB. Locally advanced breast carcinoma: results with combined regional therapy. Int J Radiat Oncol Biol Phys 1986;12:1583-7. (Pubitemid 17175242)
6. Arnold D, Lesnick G. Survival following mastectomy for stage III breast cancer. Am J Surg 1979;137:362.
7. Fracchia AA, Evans JF, Eisenberg BL. Stage III carcinoma of breast: A detailed analysis. Ann Surg 1980;192:705-10. (Pubitemid 11210689)
8. Bruckman JE, Harris JR, Levene MB, Chaffey JT, Hellman S. Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 1979;43:985-93. (Pubitemid 9163630)
9. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37:1422-31.
10. Rubens RD, Armitage P, Winter PJ, Tong D, Hayward JL. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977;13:805-11. (Pubitemid 8157071)
11. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412.
12. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456.
13. Wenzel C, Bartsch R, Locker GJ, Hussian D, Pluschnig U, Sevelda U, et al. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anticancer Drugs 2005;16:441-5. (Pubitemid 40434610)
14. Schneerweiss A, Bastert G, Huober J, Wallwiener D, Hamerla R, Lichter P. Neoadjuvant therapy with gemcitabine in breast cancer. Oncology 2004;18:27-31.
15. DeLena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G . Combined chemotherapy radiotherapy approach in locally advanced breast cancer. Cancer Chemother Pharmacol 1978;1:53-9. (Pubitemid 9025112)
16. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, et al. Neoadjuvant chemotharpy in the combined modality approach of locally advanced non metastatic breast cancer. Cancer Res 1987;47:3889-94. (Pubitemid 17105745)
17. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8. (Pubitemid 13143147)
18. Powels TJ, Hickish TF, Makris A, Asley SE, O'Brien SE, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary braest cancer. J Clin Oncol 1995;13:547-52.
19. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85. (Pubitemid 28363030)
20. Wolmark N, Wang J, Fisher B, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl CancerInst Monogr 2001;30:96-102.
21. Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukal NK, et al. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer. 2005;42:40-5.
22. Segal R, Dent SF, Verma S, Gerller S, Young V, Goel R, et al. Changing demographics of locally advanced breast cancer: Data from a regional cancer centre. ASCO 2006.
23. Erol K, Baltali E, Altundag K, Guler N, Ozisik Y, Onat DA, et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie 2005;28:81-5. (Pubitemid 40288440)
24. Deo SVS, Bhutani M, Shukla NK, Raina V, Rath GK and Purkaysth J. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer. J Surg Oncol 2003;84:192-7. (Pubitemid 37484783)
25. Baldini E, Gardin G, Giannessi P G Evangelista G, Roncella M, Prochilo T, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003;14:227-32. (Pubitemid 36305434)
26. Raina V, Taneja V, Gulati A. Estrogen receptor status in breast cancer. The Indian Practitioner 2000;53:405-07.
27. Redkar AA, Kabre SS, Mitra I. Estrogen and progesterone receptors measurement in breast cancer with enzyme-immunoassay and correlation with other prognostic factors. Indian J Med Res 1992;96:1-8.
28. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-8. (Pubitemid 46638980)
29. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9. (Pubitemid 29075229)
30. Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, et al. Treatment of large and locally advanced Breast Cancer Using Neoadjuvant Chemotherapy. Am J Surg 1998;175:127-32. (Pubitemid 28138066)